Glioblastoma (GBM), the most common primary brain tumor, is a complex and extremely aggressive disease. Despite recent advances in molecular biology, there is a lack of biomarkers, which would improve GBM’s diagnosis, prognosis, and therapy. Here, we analyzed by qPCR the expression levels of a set of miRNAs in GBM and lower-grade glioma human tissue samples and performed a survival analysis in silico. We then determined the expression of same miRNAs and their selected target mRNAs in small extracellular vesicles (sEVs) of GBM cell lines. We showed that the expression of miR-21-5p was significantly increased in GBM tissue compared to lower-grade glioma and reference brain tissue, while miR-124-3p and miR-138-5p were overexpressed in reference brain tissue compared to GBM. We also demonstrated that miR-9-5p and miR-124-3p were overexpressed in the sEVs of GBM stem cell lines (NCH421k or NCH644, respectively) compared to the sEVs of all other GBM cell lines and astrocytes. VIM mRNA, a target of miR-124-3p and miR-138-5p, was overexpressed in the sEVs of U251 and U87 GBM cell lines compared to the sEVs of GBM stem cell line and also astrocytes. Our results suggest VIM mRNA, miR-9-5p miRNA, and miR-124-3p miRNA could serve as biomarkers of the sEVs of GBM cells.

Recent research has indicated that dysbiosis of the gut microbiota can lead to an altered circadian clock of the mammalian host. Herein we developed an original system that allows real-time circadian studies of human HepG2 hepatoma cells co-cultured with bacteria. The HepG2 cells with stably integrated firefly luciferase reporter under the control of PERIOD2 promoter were co-cultured with E. coli strains isolated from human fecal samples from healthy individuals. The two E. coli strains differ in the phylogenetic group and the number of ExPEC virulence-associated genes: BJ17 has only two, and BJ23 has 15 of 23 tested. In the first 24 h, the E. coli BJ17 affected the HepG2 circadian clock more than BJ23. Cosinor analysis shows a statistically significant change in the amplitude of PER1 and 2 and the phase advance of PER3. A high percentage of necrotic and apoptotic cells occurred at 72 h, while a correlation between the number of ExPEC genes and the influence on the HepG2 core clock gene expression was observed. Our study reveals that the E. coli genetic background is important for the effect on the mammalian circadian clock genes, indicating possible future use of probiotic E. coli strains to influence the host circadian clock.

Advances in high-throughput sequencing technologies have transformed human genomics, enabling large-scale initiatives to characterise genome structure, function, and population diversity. Following foundational international projects such as the Human Genome Project, HapMap, and the 1000 Genomes Project, many countries have developed national sequencing initiatives to generate population-specific genomic resources and support precision medicine. In this review, we examine the development of human genomic sequencing initiatives with a particular focus on Europe, where national projects differ substantially in their objectives, infrastructure, governance, funding models, cohort design, and degree of integration with healthcare systems. We further consider how pan-European programmes are increasingly linking these heterogeneous national efforts through shared standards, federated data infrastructures, and coordinated population-reference initiatives. Comparisons with selected initiatives from other world regions highlight common challenges, including unequal population representation, long-term sustainability, data governance, interoperability, and translation into clinical practice. We also discuss the growing impact of long-read sequencing and artificial intelligence on population genomics and genomic medicine. Overall, the European landscape illustrates that successful genomic initiatives depend not simply on sequencing scale, but on the alignment of scientific objectives with representative recruitment, sustainable infrastructure and financing, interoperable data systems, and pathways for clinical implementation.